Showing 1,741 - 1,760 results of 9,771 for search 'significantly ((((((greater decrease) OR (mean decrease))) OR (we decrease))) OR (larger decrease))', query time: 0.45s Refine Results
  1. 1741

    DataSheet1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

    Published 2024
    “…Further, data from sleep questionnaires proved sleep-wake disruption in patients with MASLD. We objectively assessed sleep-wake rhythms in patients with biopsy-proven MASLD (n = 35) and healthy controls (HC, n = 16) using actigraphy 24/7 for 4 weeks. …”
  2. 1742

    DataSheet3_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

    Published 2024
    “…Further, data from sleep questionnaires proved sleep-wake disruption in patients with MASLD. We objectively assessed sleep-wake rhythms in patients with biopsy-proven MASLD (n = 35) and healthy controls (HC, n = 16) using actigraphy 24/7 for 4 weeks. …”
  3. 1743

    DataSheet2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

    Published 2024
    “…Further, data from sleep questionnaires proved sleep-wake disruption in patients with MASLD. We objectively assessed sleep-wake rhythms in patients with biopsy-proven MASLD (n = 35) and healthy controls (HC, n = 16) using actigraphy 24/7 for 4 weeks. …”
  4. 1744

    DataSheet4_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

    Published 2024
    “…Further, data from sleep questionnaires proved sleep-wake disruption in patients with MASLD. We objectively assessed sleep-wake rhythms in patients with biopsy-proven MASLD (n = 35) and healthy controls (HC, n = 16) using actigraphy 24/7 for 4 weeks. …”
  5. 1745
  6. 1746
  7. 1747
  8. 1748
  9. 1749
  10. 1750
  11. 1751
  12. 1752

    Each subfigure shows a different local size (LS) and context size (CS) configuration, where the reliability of the model across different initializations is measured in R-squared. by Eloy Geenjaar (21533195)

    Published 2025
    “…Moreover, reliability decreases with a larger dimensionality of the context space, likely increasing the dimensions essentially increases the size and thus the number of equivalent solutions of the space. …”
  13. 1753
  14. 1754
  15. 1755
  16. 1756

    Renal outcomes of both treatment groups. by Marwan El-Deyarbi (21688492)

    Published 2025
    “…Participants in the multifactorial group achieved a significant mean difference in low-density lipoprotein cholesterol levels (mean difference = −0.14, 95% CI: −0.27–0.001, P < 0.03), and significant adjusted mean difference of eGFR levels difference (3.93 mL/min/1.73 m<sup>2</sup>, 95% CI: 1.27–6.58, P < 0.01) at study completion compared to those in the control group. …”
  17. 1757

    Manuscript data. by Khalid A. Al-Gaadi (2826632)

    Published 2025
    “…Moreover, the total tomato fruit yield also decreased significantly at salinity-3 compared to salinity-1.…”
  18. 1758

    Sequence of <i>DpAP2</i> promoter. by Lingru Ruan (18995544)

    Published 2024
    “…It was speculated that MeJA significantly decreased expression of <i>DpAP2</i> gene, then the decreasing <i>DpAP2</i> expression significantly inhibited expression of some key enzyme genes such as <i>PSY</i>, <i>PDS</i> and <i>GGPS</i> in carotenoid biosynthesis pathway. …”
  19. 1759

    Predicted <i>cis</i>-acting elements in <i>DpAP2</i> promoter. by Lingru Ruan (18995544)

    Published 2024
    “…It was speculated that MeJA significantly decreased expression of <i>DpAP2</i> gene, then the decreasing <i>DpAP2</i> expression significantly inhibited expression of some key enzyme genes such as <i>PSY</i>, <i>PDS</i> and <i>GGPS</i> in carotenoid biosynthesis pathway. …”
  20. 1760